{
  "id": 20752161,
  "title": "CVRx at Jefferies Global Healthcare Conference: growth plan meets payer strain",
  "url": "https://urgent.news/2026/11/19/cvrx-at-jefferies-global-healthcare-conference-growth-plan-meets",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-19T13:32:27.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/cvrx-at-jefferies-global-healthcare-conference-growth-plan-meets-payer-strain-93CH-5039044"
  },
  "original_language": "en",
  "account": "On November 19, 2026, CVRx (CVRX) addressed the Jefferies Global Healthcare Conference to discuss the challenges and opportunities surrounding its Barostim heart-failure therapy. CEO Kevin Hykes reiterated the therapy's clear clinical role and large market potential, despite recent stock pressure and reimbursement setbacks. Hykes acknowledged the adoption barriers and slower-than-expected commercial rollout, but remained confident in the company's fundamentals.\n\nBarostim targets a significant heart-failure population that is not well served by drug therapy alone, estimating a $10.5 billion market today, with the potential to expand to about $30 billion if a major new trial succeeds. Reimbursement improvements, such as full Medicare fee-for-service coverage, are helping, but the largest payer has significantly reduced approvals. Sales execution is improving, with lower turnover and stronger performance in experienced regions.\n\nCVRx positions itself as a solution for the \"forgotten middle\" of heart failure patients, those who are ambulatory but face serious symptoms and poor quality of life. This group represents the middle stage of a 8- to 10-year disease journey, often treated with multiple drugs but still struggling. The therapy works by restoring baroreceptor signaling from the carotid artery to the brain, reducing the sympathetic \"fight or flight\" response common in heart failure.\n\nThe pivotal BeAT-HF trial demonstrated a 94% responder rate, 68% improvement in functional status, a two-fold clinically meaningful improvement in exercise capacity and quality of life, and a 97% implant procedure freedom from complications. With a total addressable market of $10.5 billion, CVRx is betting on better reimbursement, stronger sales coverage, and a large new trial to restore momentum. Despite reimbursement headwinds, the company maintains an impressive gross profit margin of 86.9% and strong liquidity with a current ratio of 6.8.",
  "summary": null,
  "key_points": [
    "CVRx CEO Kevin Hykes discusses Barostim therapy at Jefferies Global Healthcare Conference.",
    "Company targets $10.5 billion market for Barostim, with potential to expand to $30 billion.",
    "BeAT-HF trial showed 94% responder rate and 68% improvement in functional status."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}